Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine

Launched by GLOBAL COALITION FOR ADAPTIVE RESEARCH · Jul 5, 2023

Keywords

ClinConnect Summary

The Department of Defense is conducting a clinical trial to study the effectiveness of fluoxetine, a medication commonly used to treat depression, in people with Post Traumatic Stress Disorder (PTSD). This trial is part of a larger study that will explore different treatments for PTSD and will involve participants who are between the ages of 65 and 74 and 23 and 740. The goal is to see if fluoxetine can help relieve the symptoms of PTSD safely.

To be eligible for the trial, participants must not have recently used fluoxetine specifically for PTSD treatment, and they will be screened to ensure they meet specific criteria. Those who join the study can expect to receive either fluoxetine or a placebo (a sugar pill that looks like the medication but has no active ingredients) without knowing which one they are getting. The trial is currently recruiting participants, and it aims to contribute important information about how to better treat PTSD. If you or someone you know is interested, more details can be found by looking up the study number NCT05422612.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT05422612).
• Exclusion Criteria:
• • The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT05422612).
• • 1. Recent history of treatment for PTSD with fluoxetine at doses of 20 mg daily, for at least 4 weeks. A remote history of treatment with fluoxetine for non-PTSD symptoms will be discussed on a case-by-case basis with the contract research organization (CRO) Medical Monitor.